Lymphoma, B-Cell, Marginal Zone  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT00006473: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed
2
72
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP
National Cancer Institute (NCI)
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia
02/06
 
NCT01068392: Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

Completed
2
42
RoW
Oxaliplatin, Prednisolone
Dong-A University Hospital, Samsung Medical Center, Asan Medical Center, Chung-Ang University, Kyungpook National University Hospital, Chonnam National University Hospital, Korea Cancer Center Hospital, Korea University
B-cell Lymphomas
09/13
09/14

Download Options